Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations.

Zaja F, Carpenedo M, Baratè C, Borchiellini A, Chiurazzi F, Finazzi G, Lucchesi A, Palandri F, Ricco A, Santoro C, Scalzulli PR.

Blood Rev. 2019 Nov 30:100647. doi: 10.1016/j.blre.2019.100647. [Epub ahead of print] Review.

PMID:
31818701
2.

Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years.

Palandri F, Santoro C, Carpenedo M, Cantoni S, Barcellini W, Carli G, Carrai V, Rossi E, Rivolti E, Lucchesi A, Rotondo F, Baldacci E, Auteri G, Sutto E, Di Pietro C, Catani L, Bartoletti D, De Stefano V, Ruggeri M, Mazzucconi MG, Cavo M, Rodeghiero F, Vianelli N.

Thromb Res. 2020 Jan;185:88-95. doi: 10.1016/j.thromres.2019.11.026. Epub 2019 Nov 21.

PMID:
31783273
3.

Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia.

González-Porras JR, Godeau B, Carpenedo M.

Ther Adv Hematol. 2019 May 9;10:2040620719837906. doi: 10.1177/2040620719837906. eCollection 2019. Review.

4.

Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.

Fattizzo B, Pasquale R, Carpenedo M, Cantoni S, Auteri G, Gramegna D, D'Adda M, Napolitano M, Consonni D, Ruggeri M, Siragusa S, Rossi G, Vianelli N, Barcellini W.

Haematologica. 2019 Oct;104(10):e470-e473. doi: 10.3324/haematol.2019.216804. Epub 2019 Mar 7. No abstract available.

5.

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.

Napolitano M, Saccullo G, Marietta M, Carpenedo M, Castaman G, Cerchiara E, Chistolini A, Contino L, De Stefano V, Falanga A, Federici AB, Rossi E, Santoro R, Siragusa S; Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Working Party on Thrombosis and Hemostasis; Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Working Party on Thrombosis and Haemostasis (see Appendix 1), De Stefano V, Falanga A, Tosetto A, Avvisati G, Carpenedo M, Federici AB, Marietta M, Napolitano M, Rossi E, Santoro C, Castaman G, Cerchiara E, Chistolini A, Contino L, Mazzucconi MG, Nichele I, Russo L, Santi R, Santoro RC, Siragusa S, Tagariello G.

Blood Transfus. 2019 May;17(3):171-180. doi: 10.2450/2018.0143-18. Epub 2018 Oct 24. Review.

6.

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting.

De Stefano V, Rocca B, Tosetto A, Soldati D, Petrucci G, Beggiato E, Bertozzi I, Betti S, Carli G, Carpenedo M, Cattaneo D, Cavalca V, Dragani A, Elli E, Finazzi G, Iurlo A, Lanzarone G, Lissandrini L, Palandri F, Paoli C, Rambaldi A, Ranalli P, Randi ML, Ricco A, Rossi E, Ruggeri M, Specchia G, Timillero A, Turnu L, Vianelli N, Vannucchi AM, Rodeghiero F, Patrono C.

Blood Cancer J. 2018 Jun 1;8(6):49. doi: 10.1038/s41408-018-0078-3.

7.

Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.

Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, Cairoli R.

Am J Hematol. 2018 Jan;93(1):58-64. doi: 10.1002/ajh.24935. Epub 2017 Nov 9.

8.

Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.

Marangon M, Vianelli N, Palandri F, Mazzucconi MG, Santoro C, Barcellini W, Fattizzo B, Volpetti S, Lucchini E, Polverelli N, Carpenedo M, Isola M, Fanin R, Zaja F.

Eur J Haematol. 2017 Apr;98(4):371-377. doi: 10.1111/ejh.12839. Epub 2017 Jan 20.

PMID:
27981682
9.

Clinical relevance of antiplatelet antibodies and the hepatic clearance of platelets in patients with immune thrombocytopenia.

Cantoni S, Carpenedo M, Nichelatti M, Sica L, Rossini S, Milella M, Popescu C, Cairoli R.

Blood. 2016 Oct 27;128(17):2183-2185. Epub 2016 Sep 6. No abstract available.

PMID:
27601463
10.

Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease.

Efficace F, Mandelli F, Fazi P, Santoro C, Gaidano G, Cottone F, Borchiellini A, Carpenedo M, Simula MP, Di Giacomo V, Bergamaschi M, Vincelli ID, Rodeghiero F, Ruggeri M, Scaramucci L, Rambaldi A, Cascavilla N, Forghieri F, Petrungaro A, Ditonno P, Caocci G, Cirrincione S, Mazzucconi MG.

Am J Hematol. 2016 Oct;91(10):995-1001. doi: 10.1002/ajh.24463. Epub 2016 Jul 14.

11.

Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.

Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.

Am J Hematol. 2016 May;91(5):E293-5. doi: 10.1002/ajh.24341. Epub 2016 Apr 4.

12.

Response loss and development of neutralizing antibodies during long-term treatment with romiplostim in patients with immune thrombocytopenia: a case series.

Carpenedo M, Cantoni S, Coccini V, Pogliani EM, Cairoli R.

Eur J Haematol. 2016 Jul;97(1):101-103. doi: 10.1111/ejh.12733. Epub 2016 Feb 4.

PMID:
26718013
13.

Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study.

Riva N, Ageno W, Poli D, Testa S, Rupoli S, Santoro R, Lerede T, Piana A, Carpenedo M, Nicolini A, Ferrini PM, Martini G, Mangione C, Contino L, Bonfanti C, Gresele P, Tosetto A.

Gastroenterol Res Pract. 2015;2015:620217. doi: 10.1155/2015/620217. Epub 2015 Oct 5.

14.

Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice.

Carpenedo M, Cantoni S, Coccini V, Fedele M, Morra E, Pogliani EM.

Hematol Rep. 2015 Feb 24;7(1):5673. doi: 10.4081/hr.2015.5673. eCollection 2015 Feb 24.

15.

Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study.

Riva N, Ageno W, Poli D, Testa S, Rupoli S, Santoro R, Lerede T, Piana A, Carpenedo M, Nicolini A, Ferrini PM, Tosetto A; Italian Federation of Anticoagulation Clinics (FCSA); Italian Federation of Anticoagulation Clinics FCSA.

J Thromb Haemost. 2015 Jun;13(6):1019-27. doi: 10.1111/jth.12930. Epub 2015 May 13.

16.

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.

Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C, Revelli N, Villa MA, Consonni D, Scaramucci L, De Fabritiis P, Tagariello G, Gaidano G, Rodeghiero F, Cortelezzi A, Zanella A.

Blood. 2014 Nov 6;124(19):2930-6. doi: 10.1182/blood-2014-06-583021. Epub 2014 Sep 16.

PMID:
25232059
17.

Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis.

Ageno W, Dentali F, De Stefano V, Barco S, Lerede T, Bazzan M, Piana A, Santoro R, Duce R, Poli D, Martinelli I, Siragusa S, Barillari G, Cattaneo M, Vidili G, Carpenedo M, Rancan E, Giaretta I, Tosetto A.

Thromb Res. 2014 Jun;133(6):1052-5. doi: 10.1016/j.thromres.2014.03.044. Epub 2014 Apr 1.

PMID:
24731559
18.

The plasmablasts in Castleman disease.

Pagni F, Bosisio FM, Sala E, Cattoretti G, Isimbaldi G, Coppola S, Nespoli L, Carpenedo M, Hsi ED, Dogan A.

Am J Clin Pathol. 2013 Apr;139(4):555-9. No abstract available.

PMID:
23525622
19.

Patient preferences and willingness to pay for different options of anticoagulant therapy.

Moia M, Mantovani LG, Carpenedo M, Scalone L, Monzini MS, Cesana G, Mannucci PM.

Intern Emerg Med. 2013 Apr;8(3):237-43. doi: 10.1007/s11739-012-0844-3. Epub 2012 Aug 28.

PMID:
22926743
20.

Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1).

Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, Laurora R, Molinari AC, Prisco D, Silingardi M, Verso M, Visonà A; Italian Society for Haemostasis and Thrombosis.

Thromb Res. 2012 May;129(5):e171-6. doi: 10.1016/j.thromres.2011.09.002. Epub 2011 Oct 2.

PMID:
21962722
21.

From Vaquez to Dameshek through JAK…2 much for polycythemia vera to be feared?

Carpenedo M, Pogliani EM.

Intern Emerg Med. 2010 Oct;5(5):371-3. doi: 10.1007/s11739-010-0454-x. Epub 2010 Sep 9. No abstract available.

PMID:
20827516
22.

Attitudes to prescribing compression stockings for patients with acute DVT: the MASTER registry.

Arpaia G, Carpenedo M, Pistelli R, Mastrogiacomo O, Cimminiello C, Agnelli G.

J Thromb Thrombolysis. 2009 Nov;28(4):389-93. doi: 10.1007/s11239-009-0316-4. Epub 2009 Mar 10.

PMID:
19277470
23.

D-dimer before chemotherapy might predict venous thromboembolism.

Arpaia G, Carpenedo M, Verga M, Mastrogiacomo O, Fagnani D, Lanfredini M, Milani M, Cimminiello C.

Blood Coagul Fibrinolysis. 2009 Apr;20(3):170-5. doi: 10.1097/MBC.0b013e32831bc2de.

PMID:
19276795
24.

The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: an observational study.

Fagnani D, Bertolini A, Catena L, Tomirotti M, Visini M, Alatri A, De Paoli A, Aondio GM, Milani M, Arpaia G, Cimminiello C; POLONORD Group, Franchi R, Porta C, Pugliese P, Borgonovo K, Duro M, Ardizzoia A, Filipazzi V, Isa L, Vergani C, Carpenedo M, Viale P.

Blood Coagul Fibrinolysis. 2009 Jan;20(1):35-40. doi: 10.1097/MBC.0b013e32831bc2f8.

PMID:
20523163
25.

Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different intensity targets.

Sacco R, Sacco M, Carpenedo M, Mannucci PM.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jul;104(1):e18-21. Epub 2007 May 7.

PMID:
17482846
26.

Retrievable vena cava filters: a review.

Imberti D, Ageno W, Carpenedo M.

Curr Opin Hematol. 2006 Sep;13(5):351-6. Review.

PMID:
16888440
27.

Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different INR targets.

Sacco R, Sacco M, Carpenedo M, Moia M.

J Thromb Haemost. 2006 Mar;4(3):688-9. No abstract available.

28.
29.
30.

Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study.

Cosmi B, Palareti G, Moia M, Carpenedo M, Pengo V, Biasiolo A, Rampazzo P, Morstabilini G, Testa S.

Thromb Res. 2000 Nov 15;100(4):279-86.

PMID:
11113271
31.

Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases.

Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM.

Haemophilia. 2000 Mar;6(2):71-7.

PMID:
10781191
32.

P-Glycoprotein Expression in Acute Myeloid Leukaemia Cells at Diagnosis: Its relationship to Daunorubicin or Idarubicin Induction Therapy and Survival.

Pogliani EM, Carpenedo M, Miccolis I, Belotti D, Corneo GM.

Hematology. 2000;5(5):359-67. doi: 10.1080/10245332.2000.11746531.

PMID:
27420927
33.

[Arg506 --> Gln mutation of coagulation factor V (factor V Leiden) and transient cerebral ischemia at a young age in 3 members of the same family].

Moia M, La Spina I, Padalino R, Carpenedo M.

Ann Ital Med Int. 1996 Jan-Mar;11(1):17-9. Italian.

PMID:
8645525

Supplemental Content

Loading ...
Support Center